Systemic lupus erythematosus (SLE) is a systemic autoimmune disease, characterised by autoantibody production, complement activation and immune-complex deposition which eventually lead to tissue and organ damage (Ref. . Recently, findings suggested that the absence of IRF5 resulted in aberrant production of auto-antibodies and proinflammatory cytokines, which correlates with the pathogenesis of SLE. Furthermore, functional analysis revealed genetic association of IRF5 and SLE. The strong association of this transcription factor with autoimmune disease on multiple levels encourages us to systematically review what had been published recently on the crucial nature of IRF5 in relation to SLE gaining attention for its regulatory capability in autoimmune lupus. The information obtained may result in a better understanding of the pathogenesis and development of novel therapeutic strategies for this systemic autoimmune disease.
IRF5, a transcription factor
Murine Irf5 gene is primarily expressed as a fulllength transcript in the B220
+ mature B cells with only a single splice variant, detectable at low levels in the bone marrow (BM) (Refs 5, 6 ). This BM Mu Irf5 transcript includes a 288-nucleotide deletion in the coding region, with an impaired transcriptional activity of IRF5 (Ref. 6 ). Both Tank binding Kinase 1 (TBK1) and MyD88 can activate the murine IRF5 to generate homodimers or activate transcription of type I IFN (Ref. 6 ). Furthermore, IRF5 contributes to the expression of inflammatory cytokines such as TNFα, regulated on activation normal T cell expressed and secreted (RANTES) and IL-6 (Refs 6, 7, 8) .
Human Irf5 gene is mapped to the chromosome 7q32 (Ref. 9) (Fig. 1 ). There are 9 exons in Irf5 gene. It has a CpG island, encompassing exon 1A and 1B (there are four alternative 5 ′ UTR exons in IRF5 gene: 1A, 1B, 1C and 1D) (Ref. 9) . Of the four exons, only exon 1A transcripts are highly expressed. Therefore, it is possible that methylation of the CpG island might result in IRF5 gene being epigenetically silenced. Indeed, methylated CpG island in promoter regions has been found in lung cancer cells (increased IRF5 hyper-methylation in CRL5800, CRL5807, CRL5872 and CRL5810 cell lines) (Refs 10, 11 The structure of the human IRF5 gene. 
Protective haplotype: Recently, the A allele of rs10954213 was found to be related to the high level of IRF5 in SLE patients (Ref. 14) . In mice, mutations disrupting AREs in the tumor necrosis factor α (TNFα) gene can result in up-regulation of circulating TNFα and hypersensitivity in the presence of stimulation with TLR4 ligand lipopolysaccharide (LPS) (Refs 46, 47). Therefore, it is possible that rs10954213 in the 3 ′ UTR polyA site of IRF5 might be a functional mutation required for high levels of IRF5. IRF5 expression and alternative splicing were significantly increased in SLE patients compared with healthy controls, especially when the transcription from exon 1A and exon 1D was markedly up-regulated in the patient cells (Ref. 19) . It is known that increased serum levels of small nuclear ribonucleoproteins (snRNPs) and serine/arginine-rich (SR) proteins, which are components of the spliceosome, can be found in SLE patients (Refs 48, 49) . Following co-transfection with snRNPs or SR proteins, the transcription from exon 1A and alternative splicing of exon 5-7 were enhanced. In particular, co-transfection with U1 snRNP led to the strongest increase of IRF5 expression, implying its contribution to the enhanced alternative splicing (Ref. 19) . Furthermore, IRF5 transcript expression was higher in patients carrying the risk haplotype versus patients carrying the protective haplotype, and IRF5 protein expression was increased in myeloid DCs and monocytes from SLE patients, correlating with the risk haplotype (Ref. 19 ). In addition, the functional effects of exon 6 in/del-10 and SV-16 within IRF5 were demonstrated in SLE, where the expression of either SV-16 or in/ del-10 confers IRF5 the ability to impair apoptotic response, and is related to the downregulation of IRF5 nuclear translocation in murine embryonic fibroblasts (MEFs) after treatment with DNA-damaging stimulus (Ref. 50) . MEFs that expressed IRF5-bearing SV-16 displayed up-regulated IL-6 production upon LPS stimulation. By contrast, MEFs containing in/del-10 produced IL-6 with no significant difference from the controls. Intriguingly, the absence or presence of both in/del-10 and SV-16 leads to abrogation of these effects. Together, these observations indicate that specific genetic architecture of IRF5 correlates with the upregulated expression of IRF5 in SLE patients, and IRF5 variants carried on SLE risk haplotypes modulate IRF5 function.
IRF5 and the immune mechanisms of autoimmune lupus
It has been observed that compared with the nonlupus-prone strain of mice (C57BL (Fig. 3) .
The role of IRF5 in B cells
IRF5 deficiency in pristane-induced lupus mice did not produce IgG2b, IgG2c, IgG3, IgM anti-U1A Abs, anti-Sm/RNP auto-antibodies, antinuclear antibodies (ANA) and anti-dsDNA auto-antibodies (Refs 3, 61, 62). Similarly, the production of auto-antibodies, including ANA, anti-dsDNA antibody, anti-Sm antibody and anti-RNP antibody, was dramatically attenuated in MRL/lpr, FcγRIIB −/− Yaa and FcγRIIB 
IRF5 in T (Th) cells

Influence of IRF5 on DC immune responses
IRF5 plays an important role in DC (Fig. 4) . IRF5 
